Back

Response to SGLT2 inhibitors in heart failure with tricuspid regurgitation: clinical interpretation and future directions

European Heart Journal - Cardiovascular Pharmacotherapy

11 April 2026
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Session
Facts and perspectives in secondary tricuspid regurgitation
17 May 2025
thumbnail
Webinar
SGLT2 inhibitors across the left ventricular function spectrum
24 September 2024
thumbnail
Congress Presentation
Effects on mitral and tricuspid valve regurgitation after 6 months of treatment with SGLT2 inhibitors in patients with chronic heart failure
31 August 2025
thumbnail
Congress Presentation
Sodium-glucose co-transporter-2 inhibitors improve cardiovascular outcomes in heart failure with reduced ejection fraction regardless of ischemic etiology
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources